血小板凋亡与免疫性血小板减少症关系的研究进展

马静瑶; 陈振萍; 谷昊; 吴润晖

doi:10.13201/j.issn.1004-2806.2020.09.014

血小板凋亡与免疫性血小板减少症关系的研究进展

- 国家儿童医学中心, 首都医科大学附属北京儿童医院血液肿瘤中心, 儿童血液病与肿瘤分子分型北京市重点实验室, 儿科学国家重点学科, 儿科重大疾病研究教育部重点实验室(北京, 100045)
基金项目:
国家自然科学基金课题(No:81970111)

三生TCP中青年科研基金之春芽计划

北京市自然科学基金课题(No:7192064)

北京市医院管理局儿科学科协同发展中心“儿科专项”(No:XTZD20180205)

国家科技重大专项(No:2017ZX09304029004)

详细信息

通讯作者: 吴润晖,E-mail:wurunhui@bch.com.cn

中图分类号: R558.2

收稿日期: 2020-02-04

Research progress of the relationship between platelet apoptosis and immune thrombocytopenia

More Information

Corresponding author: WU Runhui

Received Date: 04 February 2020

摘要

- 免疫性血小板减少症 /
- 血小板凋亡 /
- 发病机制 /
- 治疗
Abstract: Immune thrombocytopenia (ITP) is an acquired autoimmune-mediated thrombocytopenia.The majority of children ITP show self-limiting process,while few undergo prolonged and recurrent natural history,similar to the majority of adults ITP,who bear heavy burden of treatment and poor prognosis.ITP is highly heterogeneous in clinical outcomes with complex mechanisms that have yet to be discovered.In recent years,it has been found that platelet apoptosis may be one of the mechanisms of chronic ITP in adults and acute ITP in children.Intravenous immunoglobulin and recombinant human thrombopoietin may affect the process of platelet apoptosis,to achieve the therapeutic purpose.In this paper,we review the role of platelet apoptosis in the pathogenesis and treatment of ITP.
- immune thrombocytopenia /
- platelet apoptosis /
- pathogenesis /
- treatment

HTML全文

参考文献(30)

[1]	Piguet PF,Vesin C.Modulation of platelet caspases and life-span by anti-platelet antibodies in mice[J].Eur J Haematol,2002,68:253-261.
[2]	Li J,van der Wal DE,Zhu G,et al.Desialylation is a mechanism of Fc-independent platelet clearance and a therapeutic target in immune thrombocytopenia[J].Nat Commun,2015,6:7737.
[3]	Yan R,Chen M,Ma N,et al.Glycoprotein Ibα clustering induces macrophage-mediated platelet clearance in the liver[J].Thromb Haemost,2015,113:107-117.
[4]	Leytin V,Allen DJ,Mutlu A,et al.Mitochondrial control of platelet apoptosis:effect of cyclosporin A,an inhibitor of the mitochondrial permeability transition pore[J].Lab Invest,2009,89:374-384.
[5]	Kile BT.The role of apoptosis in megakaryocytes and platelets[J].Br J Haematol,2014,165:217-226.
[6]	Qiao J,Liu Y,Li D,et al.Imbalanced expression of Bcl-xL and Bax in platelets treated with plasma from immune thrombocytopenia[J].Immunol Res,2016,64:604-609.
[7]	Goette NP,Glembotsky AC,Lev PR,et al.Platelet Apoptosis in Adult Immune Thrombocytopenia:Insights into the Mechanism of Damage Triggered by Auto-Antibodies[J].PLoS One,2016,11:e0160563.
[8]	Deng G,Yu S,Li Q,et al.Investigation of platelet apoptosis in adult patients with chronic immune thrombocytopenia[J].Hematology,2017,22:155-161.
[9]	Winkler J,Kroiss S,Rand ML,et al.Platelet apoptosis in paediatric immune thrombocytopenia is ameliorated by intravenous immunoglobulin[J].Br J Haematol,2012,156:508-515.
[10]	Chen M,Yan R,Zhou K,et al.Akt-mediated platelet apoptosis and its therapeutic implications in immune thrombocytopenia[J].Proc Natl Acad Sci U S A,2018,115:E10682-E10691.
[11]	Leytin V,Mykhaylov S,Starkey AF,et al.Intravenous immunoglobulin inhibits anti-glycoprotein IIb-induced platelet apoptosis in a murine model of immune thrombocytopenia[J].Br J Haematol,2006,133:78-82.
[12]	Grodzielski M,Goette NP,Glembotsky AC,et al.Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia[J].Sci Rep,2019,9:2208.
[13]	Mason KD,Carpinelli MR,Fletcher JI,et al.Programmed anuclear cell death delimits platelet life span[J].Cell,2007,128:1173-1186.
[14]	Zhao L,Liu J,He C,et al.Protein kinase A determines platelet life span and survival by regulating apoptosis[J].J Clin Invest,2017,127:4338-4351.
[15]	Roberts AW,Seymour JF,Brown JR,et al.Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition:results of a phase I study of navitoclax in patients with relapsed or refractory disease[J].J Clin Oncol,2012,30:488-496.
[16]	Souers AJ,Leverson JD,Boghaert ER,et al.ABT-[CM(72mm]199,a potent and selective BCL-2 inhibitor,achieves antitumor activity while sparing platelets[J].Nat Med,2013,9:202-208.
[17]	Gitz E,Koekman CA,van den Heuvel DJ,et al.Improved platelet survival after cold storage by prevention of glycoprotein Ibα clustering in lipid rafts[J].Haematologica,2012,97:1873-1881.
[18]	Yu S,Huang H,Deng G,et al.miR-326 targets antiapoptotic Bcl-xL and mediates apoptosis in human platelets[J].PLoS One,2015,10:e0122784.
[19]	呼小茹,陈屿,王刚,等.MicroRNAs在原发免疫性血小板减少症中作用研究进展[J].临床血液学杂志,2020,33(3):226-229.
[20]	Ple H,Landry P,Benham A,et al.The repertoire and features of human platelet microRNAs[J].PLoS One,2012,7:e50746.
[21]	Yu S,Deng G,Qian D,et al.Detection of apoptosis-associated microRNA in human apheresis platelets during storage by quantitative real-time polymerase chain reaction analysis[J].Blood Transfus,2014,12:541-547.
[22]	Justo Sanz R,Monzón Manzano E,Fernández Bello I,et al.Platelet Apoptosis and PAI-1 are Involved in the Pro-Coagulant State of Immune Thrombocytopaenia Patients Treated with Thrombopoietin Receptor Agonists[J].Thromb Haemost,2019,119:645-659.
[23]	Wang JD,Ou TT,Wang CJ,et al.Platelet apoptosis resistance and increased CXCR4 expression in pediatric patients with chronic immune thrombocytopenic purpura[J].Thromb Res,2010,126:311-318.
[24]	Kühne T.Diagnosis and management of immune thrombocytopenia in childhood[J].Hamostaseologie,2017,37:36-44.
[25]	Neunert C,Terrell DR,Arnold DM,et al.American Society of Hematology 2019 guidelines for immune thrombocytopenia[J].Blood Adv,2019,3:3829-3866.
[26]	侯明.免疫性血小板减少症的治疗进展[J].临床血液学杂志,2020,33(1):6-9.
[27]	Gilardin L,Bayry J,Kaveri SV.Intravenous immunoglobulin as clinical immune-modulating therapy[J].CMAJ,2015,187:257-264.
[28]	Erhardt JA,Erickson-Miller CL,Aivado M,et al.Comparative analyses of the small molecule thrombopoietin receptor agonist eltrombopag and thrombopoietin on in vitro platelet function[J].Exp Hematol,2009,37:1030-1037.
[29]	Mitchell WB,Pinheiro MP,Boulad N,et al.Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia[J].Am J Hematol,2014,89:E228-E234.
[30]	Alvarez Román MT,Fernández Bello I,Arias-Salgado EG,et al.Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia[J].Thromb Haemost,2014,112:65-72.